Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 3 15
Substance-Related Disorders 44 73
Substance Abuse Problem 73

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 44 D019966
NCIt 50 C16522
SNOMED-CT 68 26416006

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to eating disorder and cocaine abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Amphetamine and Buprenorphine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : 3 Data are for the U.S.

Wikipedia : 76 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Related Disease Score Top Affiliating Genes
1 eating disorder 32.4 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
2 cocaine abuse 32.2 DBH DRD2 PRL SLC6A3 SLC6A4
3 impulse control disorder 31.9 DRD2 DRD3 DRD4
4 alcohol abuse 31.7 ABCB7 BDNF DRD2 DRD3 DRD4 GABRA2
5 depression 31.3 BDNF MAOA SLC6A4
6 antisocial personality disorder 30.7 COMT DRD2 HTR1B MAOA SLC6A3 SLC6A4
7 anxiety 30.6 BDNF COMT CYP2D6 MAOA NPY SLC6A4
8 personality disorder 30.4 BDNF COMT DRD2 DRD4 HTR1B MAOA
9 movement disease 30.4 DRD2 DRD3 SLC6A3
10 pathological gambling 30.4 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
11 post-traumatic stress disorder 30.3 BDNF COMT DRD2 MAOA SLC6A4
12 borderline personality disorder 30.2 BDNF COMT HTR1B MAOA SLC6A4
13 conduct disorder 30.2 COMT DBH DRD2 DRD4 DRD5 MAOA
14 traumatic brain injury 30.2 BDNF COMT DRD2
15 brain injury 30.2 BDNF COMT DRD2
16 opiate dependence 30.2 DRD2 DRD3 SLC6A4
17 psychotic disorder 30.1 BDNF COMT CYP2D6 DRD2 DRD3 DRD4
18 gilles de la tourette syndrome 30.0 BDNF COMT DBH DRD2 DRD4 DRD5
19 generalized anxiety disorder 30.0 BDNF COMT DRD2 MAOA SLC6A4
20 mood disorder 30.0 BDNF COMT DRD2 DRD3 DRD4 HTR1B
21 tobacco addiction 30.0 COMT DRD2 MAOA SLC6A3 SLC6A4
22 bipolar disorder 30.0 BDNF COMT DBH DRD2 DRD3 DRD4
23 alexithymia 30.0 COMT DRD2 SLC6A4
24 disease of mental health 30.0 BDNF COMT CYP2D6 DRD2 DRD3 DRD4
25 avoidant personality disorder 30.0 MAOA SLC6A4
26 bipolar i disorder 29.9 BDNF COMT SLC6A4
27 tardive dyskinesia 29.9 COMT CYP2D6 DRD2 DRD3
28 anorexia nervosa 29.7 BDNF COMT NPY PRL SLC6A4
29 schizoaffective disorder 29.7 BDNF COMT DRD2 DRD3 PRL SLC6A4
30 substance dependence 29.5 BDNF CYP2D6 DRD2 DRD3 DRD4 DRD5
31 schizophrenia 29.3 BDNF COMT CYP2D6 DBH DRD2 DRD3
32 attention deficit-hyperactivity disorder 29.2 BDNF COMT CYP2D6 DBH DRD2 DRD3
33 alcohol dependence 29.2 BDNF COMT DBH DRD2 DRD3 DRD4
34 autism 29.1 BDNF COMT DBH DRD2 DRD3 DRD4
35 cannabis abuse 11.4
36 panic disorder 1 11.1
37 opioid abuse 11.1
38 antidepressant type abuse 11.1
39 hallucinogen abuse 11.1
40 phencyclidine abuse 11.1
41 amphetamine abuse 11.1
42 barbiturate abuse 11.1
43 learning disability 11.1
44 withdrawal disorder 11.0
45 hepatitis 10.3
46 early-onset schizophrenia 10.2 BDNF DRD2
47 hepatitis c 10.2
48 polysubstance abuse 10.2 COMT DRD2 DRD3
49 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
50 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 BDNF COMT CYBB DBH DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.16 ABCB7 BDNF COMT CYBB DBH DRD2
3 cardiovascular system MP:0005385 10.1 ABCB7 COMT CYBB DBH DRD2 DRD3
4 growth/size/body region MP:0005378 10.06 ABCB7 BDNF CYBB DBH DRD2 DRD3
5 endocrine/exocrine gland MP:0005379 10.02 BDNF COMT DBH DRD2 DRD5 HTR1B
6 adipose tissue MP:0005375 9.93 CYBB DBH DRD2 DRD3 HTR1B NPY
7 integument MP:0010771 9.76 BDNF DBH DRD2 GABRA2 PRL SLC6A3
8 mortality/aging MP:0010768 9.73 ABCB7 BDNF CYBB DBH DRD2 DRD3
9 nervous system MP:0003631 9.53 ABCB7 BDNF COMT CYBB DBH DRD2

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 300-62-9 5826 3007
2
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
3
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
5
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
7
Ziprasidone Approved Phase 4 146939-27-7 60854
8
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129722-12-9 60795
9
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-36-2 5760 446220
10
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
11
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
12
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
13
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
14
Disulfiram Approved Phase 4,Phase 1 97-77-8 3117
15
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
16
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 537-46-2 10836
17
Valproic Acid Approved, Investigational Phase 4,Phase 3,Not Applicable 99-66-1 3121
18
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
19
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
20
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Lorazepam Approved Phase 4 846-49-1 3958
23
Clozapine Approved Phase 4 5786-21-0 2818
24
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
25
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
26
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
27
Sofosbuvir Approved Phase 4,Phase 3 1190307-88-0 45375808
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Choline Approved, Nutraceutical Phase 4,Not Applicable 62-49-7 305
30
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
31
Heroin Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
32
Betadex Experimental Phase 4 7585-39-9 320761
33
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antitussive Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Not Applicable
46 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
50 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1051)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
4 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
5 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
6 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units Unknown status NCT01825057 Phase 4
7 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
8 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
9 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
10 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
13 Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs Completed NCT00137306 Phase 4
14 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
15 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
16 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
17 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
18 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
19 The Whole Day First Grade Program Completed NCT00257088 Phase 4
20 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
21 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
22 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
23 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
24 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
25 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
26 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
27 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
28 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
29 Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT) Completed NCT00326781 Phase 4 Nicoderm Transdermal Patch;Nicotine Nasal Spray
30 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
31 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
32 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
33 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
34 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
35 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
36 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
37 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
38 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
39 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
40 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
41 PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 Completed NCT02149888 Phase 4 Tenofovir/emtricitabine
42 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
43 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
44 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
45 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Active, not recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
46 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Enrolling by invitation NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
47 Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use Not yet recruiting NCT03266445 Phase 4 buprenorphine/naloxone
48 Telemonitoring of Uncontrolled Hypertension Not yet recruiting NCT02730052 Phase 4
49 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
50 Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

41
Testes, Brain, Cortex, Heart, Kidney, Liver, Lung

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 1451)
# Title Authors Year
1
Communitarianism and youth empowerment: Motivation for participation in a community-based substance abuse prevention coalition. ( 30506929 )
2019
2
Examining the Role of Substance Abuse in Elder Mistreatment: Results From Mistreatment Investigations. ( 27044491 )
2019
3
Understanding child protection decisions involving parents with mental illness and substance abuse. ( 29772468 )
2018
4
Primary Hip and Knee Arthroplasty in a Safety Net Hospital: Substance Abuse and Other Factors Affecting Short-term Complications. ( 29853309 )
2018
5
Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. ( 29974660 )
2018
6
Why Don't Hospitals Prioritize Substance Abuse in Their Community Benefit Programming? ( 29346190 )
2018
7
Interventions for Women With Substance Abuse Issues: A Scoping Review. ( 29426381 )
2018
8
Child maltreatment severity, chronic substance abuse, and disability status. ( 29878835 )
2018
9
Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )
2018
10
Barriers and Facilitators to Treatment Engagement Among Clients in Inpatient Substance Abuse Treatment. ( 29683040 )
2018
11
Velopharyngeal dysfunction from intranasal substance abuse: Case series and review of literature. ( 29756302 )
2018
12
Stigma as a Barrier to Substance Abuse Treatment Among Those With Unmet Need: An Analysis of Parenthood and Marital Status. ( 29307947 )
2018
13
Successful Use of Ketamine for Burst Suppression in Super Refractory Status Epilepticus Following Substance Abuse. ( 29422735 )
2018
14
Detecting Recovery Problems Just in Time: Application of Automated Linguistic Analysis and Supervised Machine Learning to an Online Substance Abuse Forum. ( 29895517 )
2018
15
Reward-Based Learning as a Function of Severity of Substance Abuse Risk in Drug-NaA^ve Youth with ADHD. ( 29924634 )
2018
16
Victimization of the Substance Abuse and Sexual Behaviors among Junior High School Students in Cambodia. ( 29845023 )
2018
17
Substance Abuse Surveillance among Construction Workers: A Proof of Concept Alternative Approach. ( 29303868 )
2018
18
Adding Resistance Training to the Standard of Care for Inpatient Substance Abuse Treatment in Men With Human Immunodeficiency Virus Improves Skeletal Muscle Health Without Altering Cytokine Concentrations. ( 29257793 )
2018
19
Ambient air pollution exposure and emergency department visits for substance abuse. ( 29958279 )
2018
20
Gender and Cultural Adaptations for Diversity: A Systematic Review of Alcohol and Substance Abuse Interventions for Latino Males. ( 29364763 )
2018
21
Redeveloping Substance Abuse Treatment for Military Personnel. ( 29779198 )
2018
22
Characteristics of Substance Abuse and Self-Injury among American Indian Adolescents Who Have Engaged in Binge Drinking. ( 29889946 )
2018
23
Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. ( 29433069 )
2018
24
Tobacco Cessation Interventions and Smoke-Free Policies in Mental Health and Substance Abuse Treatment Facilities - United States, 2016. ( 29746451 )
2018
25
Civil commitment laws for substance abuse treatment: An acceptable option? ( 29857597 )
2018
26
Web-Based Intervention to Reduce Substance Abuse and Depression: A Three Arm Randomized Trial in Mexico. ( 29768070 )
2018
27
Long-Term Implications Of A Short-Term Policy: Redacting Substance Abuse Data. ( 29863917 )
2018
28
The Untreated Addiction: Going Tobacco-Free in a VA Substance Abuse Residential Rehabilitation Treatment Program (SARRTP). ( 29721729 )
2018
29
Patterns of Substance Abuse in Offenders With Schizophrenia- Illness-Related or Criminal Life-Style? ( 29946271 )
2018
30
Cervical dystonia and substance abuse. ( 29569175 )
2018
31
Pulmonary Alveolar Proteinosis in Setting of Inhaled Toxin Exposure and Chronic Substance Abuse. ( 29607238 )
2018
32
Cultural and Social Predictors of Substance Abuse Recovery among American Indian and Non-American Indian Pregnant and Parenting Women. ( 29932824 )
2018
33
Intravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six Cases. ( 29303801 )
2018
34
A Shared Decision-Making Tool to Prevent Substance Abuse: Protocol for a Randomized Controlled Trial. ( 29326094 )
2018
35
Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation. ( 29905667 )
2018
36
The case for considering rather than ignoring race/ethnicity in substance abuse research. ( 29388881 )
2018
37
Cued for risk: Evidence for an incentive sensitization framework to explain the interplay between stress and anxiety, substance abuse, and reward uncertainty in disordered gambling behavior. ( 30357661 )
2018
38
The development of anxiety symptomatology among juvenile offenders: the roles of maternal substance abuse and unemployment. ( 30236038 )
2018
39
Comorbid Depression and Substance Abuse in Domestic Homicide: Missed Opportunities in the Assessment and Management of Mental Illness in Perpetrators. ( 30486719 )
2018
40
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. ( 29360053 )
2018
41
Veterans in substance abuse treatment program self-initiate box gardening as a stress reducing therapeutic modality. ( 29458930 )
2018
42
Employment services and substance abuse treatment. ( 29471929 )
2018
43
Substance abuse treatment engagement, completion and short-term outcomes in the Western Cape province, South Africa: Findings from the Service Quality Measures Initiative. ( 29482052 )
2018
44
Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. ( 29485302 )
2018
45
Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany. ( 29491767 )
2018
46
Abstracts presented at the Association for Medical Education and Research in Substance Abuse (AMERSA) 41st Annual Conference, Washington, DC, USA, November 2017. ( 29509099 )
2018
47
Machine Learning of Functional Magnetic Resonance Imaging Network Connectivity Predicts Substance Abuse Treatment Completion. ( 29529409 )
2018
48
Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain. ( 29556830 )
2018
49
Evaluation of the Substance Abuse Research and Education Training (SARET) program: Stimulating health professional students to pursue careers in substance use research. ( 29565782 )
2018
50
Can We Predict Which Adolescents Will Engage in Outpatient Substance Abuse Treatment? ( 29568221 )
2018

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2
Show member pathways
12.82 COMT DRD2 DRD3 DRD4 DRD5 MAOA
3
Show member pathways
12.65 BDNF DRD2 DRD3 DRD4 DRD5
4 12.19 DRD2 DRD3 DRD4 DRD5
6 12.01 BDNF MAOA SLC6A4 TF
7
Show member pathways
11.96 BDNF DRD2 DRD5 HTR1B NPY
8
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
9 11.82 CYP2D6 HTR1B MAOA SLC6A4
10
Show member pathways
11.78 DRD2 DRD3 DRD4
11 11.71 DBH MAOA TDO2
12
Show member pathways
11.61 COMT DBH MAOA
13
Show member pathways
11.61 DRD2 DRD3 DRD4 DRD5 HTR1B
14
Show member pathways
11.56 COMT CYP2D6 SLC6A4
15 11.06 HTR1B MAOA SLC6A4
16
Show member pathways
10.89 COMT DBH MAOA
17 10.84 DRD2 DRD3 DRD5
18
Show member pathways
10.77 COMT MAOA
19 10.73 COMT MAOA
20
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
21
Show member pathways
10.65 DBH MAOA SLC6A3 SLC6A4 TDO2

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CYBB DRD2 DRD3 DRD4 DRD5 GABRA2
2 axon GO:0030424 9.83 BDNF COMT DRD2 GABRA2 SLC6A3
3 endocytic vesicle GO:0030139 9.63 DRD2 DRD3 TF
4 integral component of postsynaptic membrane GO:0099055 9.58 DRD2 SLC6A3 SLC6A4
5 integral component of presynaptic membrane GO:0099056 9.46 DRD2 HTR1B SLC6A3 SLC6A4
6 serotonergic synapse GO:0099154 9.32 HTR1B SLC6A4
7 dendrite GO:0030425 9.17 BDNF COMT CYBB DRD2 DRD4 GABRA2
8 dopaminergic synapse GO:0098691 9.13 DRD2 DRD3 SLC6A3
9 integral component of membrane GO:0016021 10.21 ABCB7 COMT CYBB CYP2D6 DBH DRD2

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.91 DBH DRD4 DRD5 GABRA2 HTR1B NPY
2 cellular calcium ion homeostasis GO:0006874 9.88 DRD3 DRD4 DRD5
3 response to nutrient GO:0007584 9.87 CYBB PRL SLC6A4
4 locomotory behavior GO:0007626 9.87 DBH DRD2 DRD3 SLC6A3
5 memory GO:0007613 9.86 BDNF DBH SLC6A4
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 DRD4 HTR1B NPY
7 social behavior GO:0035176 9.82 DRD3 DRD4 SLC6A4
8 visual learning GO:0008542 9.82 DBH DRD2 DRD3
9 neurotransmitter transport GO:0006836 9.81 GABRA2 SLC6A3 SLC6A4
10 response to ethanol GO:0045471 9.8 DRD2 DRD3 HTR1B PRL SLC6A3
11 feeding behavior GO:0007631 9.77 DRD2 HTR1B NPY
12 associative learning GO:0008306 9.77 DBH DRD2 DRD5
13 negative regulation of blood pressure GO:0045776 9.76 DRD2 DRD3 DRD5
14 arachidonic acid secretion GO:0050482 9.75 DRD2 DRD3 DRD4
15 behavioral response to cocaine GO:0048148 9.73 DRD2 DRD3 DRD4
16 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3 DRD4
17 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD2 DRD3
18 response to pain GO:0048265 9.71 COMT DBH
19 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
20 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3 DRD4
21 vasoconstriction GO:0042310 9.7 HTR1B SLC6A4
22 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
23 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
24 synaptic transmission, dopaminergic GO:0001963 9.7 DRD2 DRD3 DRD5
25 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.69 DRD3 DRD4
26 prepulse inhibition GO:0060134 9.69 DRD2 DRD3 SLC6A3
27 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 DRD5
28 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
29 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
30 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 SLC6A3
31 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
32 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
33 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR1B
34 G protein-coupled receptor internalization GO:0002031 9.67 DRD2 DRD3 HTR1B
35 negative regulation of voltage-gated calcium channel activity GO:1901386 9.66 DRD2 DRD4
36 drinking behavior GO:0042756 9.66 DRD2 HTR1B
37 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.65 DRD2 DRD5
38 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.65 DRD2 DRD3 DRD4
39 response to cocaine GO:0042220 9.65 DRD2 DRD3 DRD5 HTR1B SLC6A3
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.64 DRD2 DRD3
41 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3
42 behavioral response to ethanol GO:0048149 9.63 DBH DRD2 DRD4
43 acid secretion GO:0046717 9.62 DRD2 DRD3
44 fear response GO:0042596 9.62 DBH DRD4
45 dopamine metabolic process GO:0042417 9.62 COMT DRD2 DRD3 DRD4
46 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.61 DRD2 DRD3
48 response to drug GO:0042493 9.56 COMT CYBB DRD2 DRD3 HTR1B PRL
49 response to amphetamine GO:0001975 9.55 DBH DRD2 DRD3 DRD4 DRD5
50 response to histamine GO:0034776 9.54 DRD2 DRD3 DRD4

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 CYBB CYP2D6 DBH MAOA TDO2
2 G protein-coupled receptor activity GO:0004930 9.85 DRD2 DRD3 DRD4 DRD5 HTR1B NPY
3 drug binding GO:0008144 9.63 CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
4 adrenergic receptor activity GO:0004935 9.48 DRD2 DRD3
5 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 serotonin binding GO:0051378 9.4 HTR1B SLC6A4
8 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3 DRD4 DRD5
10 dopamine binding GO:0035240 9.02 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Substance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....